Table 2.

Binary logistical regression for odds of pCR after neoadjuvant chemotherapy by HR-status, combined MAQC and MDACCSS cohorts^*

Characteristic	HR-positive/HER2-negative				Triple-negative
	Odds Ratio	95% CI for OR		P	Odds Ratio	95% CI for OR		P
		Low	High			Low	High
Tumor size at diagnosis (TNM)								.017
T0/T1/T2					1
T3/T4					0.44	0.23	0.87
Modified Black’s Nuclear Grade				.001
1–2	1
3	4.30	1.78	10.42
PAM50 Intrinsic Subtype				.580				.898
Luminal A	1				1
Luminal B	1				1
HER2-enriched	1				1
Normal	1				1
Basal	1.32	0.49	3.58		1.06	0.42	2.61
LDHB (0.60 threshold)				.018
Low	1
High	2.86	1.19	6.84
LDHB (0.94 threshold)								.004
Low					1
High					3.18	1.45	6.99

^*Characteristics were included in the models if P ≤ .05 by univariate analysis in at least one cohort (Table 1) or the combined cohort. Cases were excluded if all characteristics were not reported. The odds ratios were not statistically significant if basal-like and luminal B cases were considered as one group.